Neurofibromatosis Clinical Trial
Official title:
Quality of Friendships in Children With Neurofibromatosis: Relationship to Disease Severity
The aim of this study is to determine if children with a higher disease severity have lower
quality friendships than children who are less severely affected and children who are
unaffected. Researchers will test the hypothesis that the quality of friendships is
inversely related to their disease severity.
Specific Aims:
1. To use the FQQ to determine if the quality of friendships in children with NF1 is lower
than the quality of friendships in unaffected children.
2. To use a disease severity scale and the FQQ to determine if children who are less
severely affected have higher friendship qualities than children who are more severely
affected.
You (your) child will be asked to complete a short questionnaire (40 questions) about their
relationship with their best friend. Doctors will review your (child's) medical chart to
find out how severe the disease is, so that this may be compared to the answers you have
(your child has) given on the friendship questionnaire.
This is an Investigational Study. About 90-100 children and adolescents with NF-1 will be
asked to take part in this study. All will be enrolled at M.D. Anderson.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00754780 -
Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
|
Phase 2 | |
Completed |
NCT00589784 -
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
|
Phase 2 | |
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Completed |
NCT01673009 -
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
|
Phase 2 | |
Recruiting |
NCT00598351 -
Natural History Study of Patients With Neurofibromatosis Type 2
|
||
Completed |
NCT02298270 -
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
|
N/A | |
Terminated |
NCT01402817 -
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
|
Phase 2 | |
Completed |
NCT02101736 -
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
|
Phase 2 | |
Completed |
NCT01633008 -
Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain
|
Early Phase 1 | |
Terminated |
NCT04461886 -
A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
|
Phase 3 | |
Completed |
NCT01275586 -
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
|
Early Phase 1 | |
Completed |
NCT02435628 -
Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF
|
N/A | |
Active, not recruiting |
NCT01140360 -
Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
|
Phase 1/Phase 2 | |
Completed |
NCT02211768 -
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
|
Phase 1 | |
Completed |
NCT01639950 -
Validating Pain Scales in Children and Young Adults
|